Develops therapies for autoimmune and inflammatory disorders by targeting the CD6-ALCAM pathway to modulate immune responses.
Equillium, Inc. is a dynamic clinical-stage biotechnology firm specializing in the development and commercialization of therapies targeting severe autoimmune and immuno-inflammatory disorders where significant medical needs persist.
Central to Equillium's pipeline is itolizumab (EQ001), an innovative monoclonal antibody that uniquely targets the CD6 immune checkpoint receptor. This lead candidate is currently undergoing Phase III clinical trials for acute graft-versus-host disease, following successful Phase Ib trials for asthma and lupus nephritis treatment. Additionally, Equillium is advancing EQ101 for cutaneous T cell lymphoma and alopecia areata, alongside EQ102 aimed at various gastrointestinal conditions.
Originally established as Attenuate Biopharmaceuticals, Inc., the company rebranded as Equillium, Inc. in 2017. Based in La Jolla, California, Equillium has rapidly established itself as a frontrunner in biotechnology, leveraging cutting-edge research and strategic partnerships to drive therapeutic innovation in autoimmune and inflammatory diseases. Since its inception in 2017, Equillium has demonstrated a commitment to pioneering treatments that address critical gaps in medical care, with a vision to enhance patient outcomes globally.